Latest Breaking News On - Rogerj pomerantz - Page 1 : comparemela.com

Yonkers ContraFect Corp posts $7 6M Q2 net loss - Westfair Communications

ContraFect Corp. (NASDAQ: CFRX), a Yonker-headquartered clinical-stage biotechnology company focused on developing new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, reported a net loss was $7.6 million, or a loss of $1.94 per share, for the second quarter.

Rogerj pomerantzContrafect corp

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesRogerj pomerantzMichael messingerExchange commission onContrafect corporation nasdaqCompany annual report on formContrafect corporationExchange commissionFect corporationChief executive officerCoagulase negative staphylococciBreakthrough therapyNasdaq capital marketsQuarterly reportMonths ended juneAccepted accounting principles

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesRogerj pomerantzMichael messingerExchange commissionContrafect corporation nasdaqDrug administration antibiotic resistance isolate bankContrafect corporationChief executive officerDisease controlCoagulase negative staphylococciAnnual reportRelations contacts

ContraFect (CFRX) Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

ContraFect (CFRX) Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichael messingercontrafect corporationtelGarrett nicholsContrafect dlasRogerj pomerantzUs department of healthHuman servicesBiomedical advanced researchContrafect corporationAdministration for strategic preparednessDevelopment authorityExchange commissionContrafect corporation nasdaqWall streetFect corporationDirect lysis

ContraFect (CFRX) Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

ContraFect (CFRX) Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rogerj pomerantzContrafect corporation nasdaqHealth productsWall streetFect corporationFrench national agencyClinical trial applicationCoagulase negative staphylococciChief executive officer